Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab
Avtorji:ID Popović, Peter, Clinical Institute of Radiology, University Medical Centre Ljubljana , Ljubljana , Slovenia Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia (Avtor)
ID Kalamutova, Ana, Department of Abdominal Surgery, University Medical Centre Ljubljana , Ljubljana , Slovenia (Avtor)
ID Djokić, Mihajlo, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia Department of Abdominal Surgery, University Medical Centre Ljubljana , Ljubljana , Slovenia (Avtor)
ID Cuderman, Anka, Department of Nuclear Medicine, University Medical Centre Ljubljana , Ljubljana , Slovenia (Avtor)
ID Boltezar, Gasper, Diagnostic Center Bled Group , Bled , Slovenia (Avtor)
ID Trotovsek, Blaz, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia Department of Abdominal Surgery, University Medical Centre Ljubljana , Ljubljana , Slovenia (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://www.sciendo.com/pdf/10.2478/raon-2026-0015
 
.pdf PDF - Predstavitvena datoteka, prenos (670,04 KB)
MD5: 3EA8222D9FC0F0B6F93E8D187CFC51B6
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo DRO - Društvo radiologije in onkologije
Povzetek:Background: The current Barcelona Clinic Liver Cancer (BCLC) classification recommends systemic treatment with atezolizumab and bevacizumab as the first-line therapy for advanced hepatocellular carcinoma (HCC). Recent studies suggest that combining systemic immunotherapy with locoregional treatments, such as transarterial radioembolization (TARE), may enhance immune responses and improve overall treatment outcomes. This article presents a case series of three patients with advanced hepatocellular carcinoma who were treated with transarterial radioembolization followed by atezolizumab and bevacizumab achieving conversion to surgical resection. Patients and methods: Between June 2020 and April 2024, three patients with advanced HCC were treated with TARE followed by atezolizumab and bevacizumab. The cohort included: Patient 1: A 59-year-old female, with noncirrhotic liver, with a 12 cm tumor and a 1.5 cm satellite lesion located in the liver, with hepatic vein and inferior vena cava (IVC) tumor thrombosis (Vv3 Japanese classification) and a small lung metastasis. Patient 2: A 63-year-old male with chronic hepatitis C (CHV), presenting with a 10 cm tumor and portal vein tumor thrombosis (Vp4 Japanese classification). Patient 3: A 50-year-old male, with non-cirrhotic liver, with a 17 cm tumor with portal vein and IVC tumor thrombosis (Vp3, Vv3 Japanese classification). Results: The combined treatment approach enabled surgical resection in all three patients, each achieving a complete pathological response. Interestingly, follow-up dosimetric analysis showed that all tumors had received a subtherapeutic absorbed radiation doses. Conclusions: In selected patients, combining transarterial radioembolization with systemic immunotherapy may enable conversion to surgical resection in advanced hepatocellular carcinoma, even with subthreshold tumor radiation doses, highlighting a potential synergistic and abscopal effect between locoregional and systemic therapies.
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.03.2026
Založnik:Association of Radiology and Oncology
Št. strani:str. 40-48
Številčenje:Vol. 60, no. 1
Izvor:Ljubljana
PID:20.500.12556/DiRROS-30283 Novo okno
eISSN:1581-3207
DOI:10.2478/raon-2026-0015 Novo okno
Datum objave v DiRROS:18.06.2026
Število ogledov:41
Število prenosov:20
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Nazaj